Verve Medical

Verve Medical, Inc., founded in 2011 by Richard Heuser and Terry Buelna, is a medical device company focused on developing treatments for uncontrolled hypertension. The company is headquartered in Phoenix, Arizona, and operates within the health care equipment sector. Since its inception, Verve Medical has secured approximately $3.63 million in funding over several seed rounds to support its research and development efforts.

The company's core business revolves around the development and commercialization of renal denervation devices. This treatment targets overactive nerves in the kidneys, which are a known cause of high blood pressure. By delivering energy to these nerves, the procedure aims to decrease their activity and help regulate blood pressure. Verve Medical serves patients with uncontrolled hypertension who may not be responding to traditional therapies.

Verve Medical's principal product is the Verve RPD™ Renal Pelvic Denervation System. A distinguishing feature of this system is its transurethral approach, accessing the renal nerves through the urethra in a manner similar to common urological procedures. This method targets the dense network of nerves in the renal pelvis, which contrasts with other renal denervation techniques that approach nerves through the renal artery. In July 2023, the company received Investigational Device Exemption (IDE) approval from the U.S. Food & Drug Administration (FDA) to commence a pivotal trial for its device, a significant milestone intended to evaluate the safety and efficacy of the system for treating uncontrolled hypertension.

Keywords: medical devices, renal denervation, hypertension treatment, high blood pressure, transurethral device, urology, medical technology, cardiovascular health, clinical trials, FDA approval, minimally invasive procedure, nerve ablation, healthcare equipment, Richard Heuser, Terry Buelna, Verve RPD system, Phoenix Arizona, medical innovation, blood pressure regulation, sympathetic nervous system